Recent Updates
Recently added Catalysts

Isoglycemic Clamp

Phase 1

Diabetes | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: Jul 23, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLED
Total Trials1
Total Enrollment36
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01152242Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)PHASE1 COMPLETED 36Aug 1, 2010May 1, 2012Jul 23, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Part I: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action)
Baseline and 30 hours
Part II: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR (AUC of glucose infusion rate), GIRmax (maximum level of glucose infusion rate), over the duration of action of glargine
Baseline and 30 hours
Secondary Endpoints
Part I: The within-subject coefficient of variation in time-action profile of glargine for AUC-GIR and GIRmax over the duration of action of glargine
Baseline and 30 hours
Part II: The within-subject standard deviation in duration of action of glargine (the difference between onset of action and end of action)
Baseline and 30 hours
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part 1ACTIVE_COMPARATORPart I of the trial
Part 2ACTIVE_COMPARATORPart II of the trial
Interventions
NameTypeDescription
Isoglycemic ClampDRUGIsoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
Comparator: insulin glargineDRUGInsulin glargine at 0.4 U/kg
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexMALE
Healthy VolunteersNo

Inclusion Criteria: Part 1: * Patient is a male between 18 to 45 years of age (inclusive) at the prestudy (screening) visit * Patient has a clinical diagnosis of type 1 diabetes * Patient must have been treated with insulin since diagnosis and be on a stable dose of insulin * Patient has a Body Ma...

Unlock Eligibility Criteria